Posterior reversible encephalopathy syndrome in an oncological normotensive patient: evidence for a pathogenic role of concomitant low magnesium serum levels and chemotherapy treatment.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
11 May 2020
11 May 2020
Historique:
received:
18
07
2019
accepted:
21
07
2019
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
30
3
2021
Statut:
epublish
Résumé
Posterior reversible encephalopathy (PRES) is a rare syndrome characterized by headache, confusion, seizures, visual changes and white matter edema at radiological imaging. Its pathophysiology is not clarified and different causes, including uncontrolled hypertension, eclampsia, chemotherapy and hypomagnesemia have been suggested. A woman affected by stage IV breast cancer with lower extremity deep vein thrombosis treated with low-molecular-weight-heparin, currently in therapy with Palbociclib/Fulvestrant (antiCDK4 and 6/estrogen receptor antagonist) but previously treated with several other chemotherapy lines (including VEGF inhibitor bevacizumab), was admitted to our Internal Medicine department because of ascites and abdominal pain. She was treated with diuretics (and paracentesis). Recently (six-month earlier) a pan-encephalic radiotherapy was done because of brain and skull metastasis. Among blood tests, low serum levels of hypomagnesemia were observed. She developed PRES that rapidly progressed to lethargy, unresponsiveness till coma without changes in blood pressure. Magnetic Resonance Imaging study showed bilateral parieto-occipital edema and a thrombosis of left transverse and sigmoid sinuses. Anti-edema therapy, intravenous supplementation of magnesium and decoagulation were started, with complete and rapid recovery (within 18 hours) of clinical and radiologic changes. PRES diagnosis was based on the rapid clinical recovery after antiedema treatment and magnesium supplementation. Low magnesium level related to both diuretic and Fulvestrant/Palbociclib therapies and recent radiotherapy can represent potential mechanisms favouring PRES development. The previous bevacizumab treatment may also be involved as a PRES predisposing factor. The concomitant occurrence of cerebral thrombosis can have precipitated the clinical situation.
Sections du résumé
BACKGROUND
BACKGROUND
Posterior reversible encephalopathy (PRES) is a rare syndrome characterized by headache, confusion, seizures, visual changes and white matter edema at radiological imaging. Its pathophysiology is not clarified and different causes, including uncontrolled hypertension, eclampsia, chemotherapy and hypomagnesemia have been suggested.
CASE REPORT
METHODS
A woman affected by stage IV breast cancer with lower extremity deep vein thrombosis treated with low-molecular-weight-heparin, currently in therapy with Palbociclib/Fulvestrant (antiCDK4 and 6/estrogen receptor antagonist) but previously treated with several other chemotherapy lines (including VEGF inhibitor bevacizumab), was admitted to our Internal Medicine department because of ascites and abdominal pain. She was treated with diuretics (and paracentesis). Recently (six-month earlier) a pan-encephalic radiotherapy was done because of brain and skull metastasis. Among blood tests, low serum levels of hypomagnesemia were observed. She developed PRES that rapidly progressed to lethargy, unresponsiveness till coma without changes in blood pressure. Magnetic Resonance Imaging study showed bilateral parieto-occipital edema and a thrombosis of left transverse and sigmoid sinuses. Anti-edema therapy, intravenous supplementation of magnesium and decoagulation were started, with complete and rapid recovery (within 18 hours) of clinical and radiologic changes.
CONCLUSIONS
CONCLUSIONS
PRES diagnosis was based on the rapid clinical recovery after antiedema treatment and magnesium supplementation. Low magnesium level related to both diuretic and Fulvestrant/Palbociclib therapies and recent radiotherapy can represent potential mechanisms favouring PRES development. The previous bevacizumab treatment may also be involved as a PRES predisposing factor. The concomitant occurrence of cerebral thrombosis can have precipitated the clinical situation.
Identifiants
pubmed: 32420975
doi: 10.23750/abm.v91i2.8685
pmc: PMC7569613
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-372Références
Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):384-8
pubmed: 27371132
J Neurochem. 1995 Feb;64(2):802-9
pubmed: 7830074
J Hypertens. 2000 Sep;18(9):1177-91
pubmed: 10994748
QJM. 2012 Jan;105(1):69-75
pubmed: 21865314
Hematol Rep. 2018 Nov 06;10(4):7257
pubmed: 30542527
J Neurol. 2008 Feb;255(2):295-6
pubmed: 18283405
J Neurol. 2017 Feb;264(2):237-242
pubmed: 27815684
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
pubmed: 16514715
Neurosci Lett. 2003 May 8;341(3):189-92
pubmed: 12697280
Neurology. 2017 Feb 21;88(8):789-796
pubmed: 28122904
Arch Argent Pediatr. 2015 Oct;113(5):e271-4
pubmed: 26294160
Intern Med J. 2005 Feb;35(2):83-90
pubmed: 15705136
J Clin Oncol. 2013 Jul 10;31(20):e360-3
pubmed: 23733774
Intern Med. 2018 Aug 15;57(16):2403-2407
pubmed: 29526944
West J Emerg Med. 2015 Jan;16(1):5-10
pubmed: 25671001
J Clin Chem Clin Biochem. 1980 May;18(5):257-70
pubmed: 7000968
J Am Soc Nephrol. 2010 Aug;21(8):1381-9
pubmed: 20538785
Lancet Neurol. 2015 Sep;14(9):914-925
pubmed: 26184985
Mol Neurobiol. 2019 Oct;56(10):6792-6806
pubmed: 30924075
J Clin Rheumatol. 2013 Sep;19(6):334-40
pubmed: 23965484
Acta Neurochir Suppl. 2006;96:402-6
pubmed: 16671494
Ann Afr Med. 2018 Apr-Jun;17(2):94-95
pubmed: 29536965
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2106-11
pubmed: 12578959
J Clin Oncol. 2012 Feb 20;30(6):e76-8
pubmed: 22203769
Cerebellum. 2013 Aug;12(4):587-8
pubmed: 23184528
Pregnancy Hypertens. 2017 Jan;7:44-49
pubmed: 28279447
Am J Nephrol. 2014;40(1):75-83
pubmed: 25059491
Handb Clin Neurol. 2017;141:467-483
pubmed: 28190431
Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):36-8
pubmed: 25979822
J Assoc Physicians India. 2017 Apr;65(4):90-92
pubmed: 28527174
AJNR Am J Neuroradiol. 2008 Jun;29(6):1043-9
pubmed: 18403560
Neuroradiology. 2017 Apr;59(4):379-386
pubmed: 28289809
Magnesium. 1984;3(4-6):215-25
pubmed: 6399343
Neurology. 1998 Nov;51(5):1369-76
pubmed: 9818862
Medicine (Baltimore). 2017 Apr;96(16):e6690
pubmed: 28422884
Magnesium. 1987;6(3):113-27
pubmed: 3306178
Am J Kidney Dis. 2010 Jul;56(1):168-74
pubmed: 20493607
Magnes Res. 2006 Sep;19(3):199-215
pubmed: 17172010
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):130-133
pubmed: 29915651
J Oncol Pharm Pract. 2016 Dec;22(6):806-810
pubmed: 26467267
Case Rep Med. 2018 Nov 29;2018:1980638
pubmed: 30631367
Magnes Res. 2010 Jun;23(2):73-80
pubmed: 20513641
Case Rep Oncol Med. 2012;2012:819546
pubmed: 23243534
Handb Exp Pharmacol. 2009;(190):159-70
pubmed: 19096776
BMC Neurol. 2018 Nov 12;18(1):190
pubmed: 30419835
N Engl J Med. 1996 Feb 22;334(8):494-500
pubmed: 8559202